Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by RenovoRx, Inc.

< Previous 1 2 Next >
RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Highlights Key Leadership Promotions
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx CEO Issues Letter to Shareholders
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Closes $6.1 Million Private Placement
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Reports Second Quarter 2023 Financial Results and Operational Highlights
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
From RenovoRx, Inc.
Via Business Wire
Tickers ASX:IMU RNXT
RenovoRx Announces New Positive Interim Phase III Data Demonstrating RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Appoints Margaret A. Tempero, M.D., to Scientific Advisory Board
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Announces ROTH Capital Key Opinion Leader (KOL) Webcast on June 15
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Initiates Patient Enrollment at University of Texas Southwestern Medical Center for Pivotal Phase III TIGeR-PaC Clinical Trial
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Announces Late-Breaking Oral Presentation at 2023 ESMO World Congress on Gastrointestinal Cancer
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx to Present at the LD Micro Invitational XIII Conference
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Reports First Quarter 2023 Financial Results and Operational Highlights
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Sponsors Pancreatic Cancer Action Network’s PurpleStride® Event
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx to Participate in the Aegis Capital Virtual Conference on May 3, 2023
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Appoints Former Chief Medical Officer of Schering-Plough, Robert J. Spiegel, MD, FACP, to Board of Directors
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study at American Association for Cancer Research Annual Meeting Underway in Orlando, Florida
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx, Inc. Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Announces Positive New Data from Phase III Clinical Trial Interim Analysis: 60% Survival Benefit and Fewer Side Effects than Systemic Chemotherapy
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGemTM as a Treatment Option for Locally Advanced Pancreatic Cancer
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Reports Full Year 2022 Financial Results and Achievement of Important Phase III Clinical Study Milestone
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx to Present at the 35th Annual Roth Conference on March 13, 2023
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.